• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.

作者信息

Ottaiano Alessandro, Capuozzo Maurizio, Nasti Guglielmo, Maiolino Piera, De Angelis Valentina, Scala Stefania, Iaffaioli Rosario V

机构信息

Department of Colorectal Oncology at the National Cancer Institute, "G. Pascale" foundation, via M. Semmola Naples, Italy.

出版信息

Front Immunol. 2013 Jan 7;3:409. doi: 10.3389/fimmu.2012.00409. eCollection 2012.

DOI:10.3389/fimmu.2012.00409
PMID:23316197
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3539668/
Abstract
摘要

相似文献

1
Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.转移性结直肠癌中抗表皮生长因子受体（EGFR）抗体反应的预测：超越EGFR抑制作用
Front Immunol. 2013 Jan 7;3:409. doi: 10.3389/fimmu.2012.00409. eCollection 2012.
2
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.表皮生长因子受体（EGFR）基因拷贝数可预测RAS野生型及RAS/ BRAF/PIK3CA野生型转移性结直肠癌患者对抗表皮生长因子受体治疗的反应。
Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.
3
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.KRAS、NRAS、BRAF、PIK3CA和PTEN对转移性结直肠癌抗表皮生长因子受体治疗的预测价值：一项系统评价和荟萃分析。
Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25.
4
Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.表皮生长因子受体双探针原位杂交联合下游基因检测预测转移性结直肠癌患者抗表皮生长因子受体治疗的疗效。 （[corrected]：原文存在一处笔误，应将“epidermal”改为“epidermal growth factor receptor”。）
Arch Med Res. 2014 Jul;45(5):366-74. doi: 10.1016/j.arcmed.2014.05.004. Epub 2014 May 13.
5
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.KRAS 状态作为抗 EGFR 抗体反应决定因素及转移性结直肠癌中联合化疗影响的系统评价和荟萃分析。
Eur J Cancer. 2011 Jun;47(9):1343-54. doi: 10.1016/j.ejca.2011.03.031. Epub 2011 May 5.
6
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.转移性结直肠癌中抗 EGFR 单克隆抗体的再治疗：不同策略的系统评价。
Cancer Treat Rev. 2019 Feb;73:41-53. doi: 10.1016/j.ctrv.2018.12.006. Epub 2018 Dec 27.
7
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.转移性结直肠癌中除KRAS状态及抗表皮生长因子受体治疗反应之外的因素
Pharmacogenomics. 2014 May;15(7):1043-52. doi: 10.2217/pgs.14.66.
8
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.表皮生长因子受体（EGFR）[更正]致癌途径的综合分子剖析，以预测转移性结直肠癌对 EGFR 靶向单克隆抗体的反应。
Target Oncol. 2010 Mar;5(1):19-28. doi: 10.1007/s11523-010-0138-5. Epub 2010 Apr 11.
9
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.单克隆抗体在转移性结直肠癌治疗中的应用：综述。
Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012.
10
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.用于治疗转移性结直肠癌的表皮生长因子受体单克隆抗体
Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742.

本文引用的文献

1
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.直接和免疫介导的针对结直肠癌细胞系面板中 ERBB 受体的抗体靶向。
Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):21046-51. doi: 10.1073/pnas.1218750110. Epub 2012 Dec 3.
2
Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.晚期结直肠癌患者 Fc 受体 IIIa 多态性与抗 EGFR 抗体的反应和临床结局相关。
J Transl Med. 2012 Nov 21;10:232. doi: 10.1186/1479-5876-10-232.
3
Combination strategies to enhance antitumor ADCC.增强抗肿瘤 ADCC 的联合策略。
Immunotherapy. 2012 May;4(5):511-27. doi: 10.2217/imt.12.38.
4
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.表皮生长因子受体靶向抗体西妥昔单抗激活促肿瘤 2 型巨噬细胞。
Clin Cancer Res. 2011 Sep 1;17(17):5668-73. doi: 10.1158/1078-0432.CCR-11-0239. Epub 2011 Jul 25.
5
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.KRAS、BRAF、PIK3CA 和 PTEN 基因突变：对转移性结直肠癌靶向治疗的影响。
Lancet Oncol. 2011 Jun;12(6):594-603. doi: 10.1016/S1470-2045(10)70209-6. Epub 2010 Dec 14.
6
The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.单克隆抗体在结直肠癌中的不断演变的作用：早期的推测和对临床试验开发的影响。
Oncologist. 2010;15(1):73-84. doi: 10.1634/theoncologist.2009-0167. Epub 2010 Jan 12.
7
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.FcγRIIa-FcγRIIIa基因多态性和KRAS突变对接受西妥昔单抗联合伊立替康治疗的转移性结直肠癌患者临床结局的影响
J Clin Oncol. 2009 Mar 1;27(7):1122-9. doi: 10.1200/JCO.2008.18.0463. Epub 2009 Jan 21.
8
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.FCGR2A和FCGR3A基因多态性与接受单药西妥昔单抗治疗的表皮生长因子受体表达型转移性结直肠癌患者的临床结局相关。
J Clin Oncol. 2007 Aug 20;25(24):3712-8. doi: 10.1200/JCO.2006.08.8021.
9
Diversity of human immune system multigene families and its implication in the genetic background of rheumatic diseases.
Curr Med Chem. 2007;14(4):431-9. doi: 10.2174/092986707779941041.
10
A functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies.对于抗葡萄糖-6-磷酸异构酶抗体呈阳性的个体，Fcγ受体IIIA的一种功能性变体与类风湿性关节炎相关。
Arthritis Res Ther. 2005;7(6):R1183-8. doi: 10.1186/ar1802. Epub 2005 Aug 11.